South Korea probing two deaths after AstraZeneca's Covid-19 vaccine
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[SEOUL] South Korean authorities said on Wednesday they are investigating the deaths of two people after a media report said the pair - both with pre-existing conditions - died within days of receiving AstraZeneca's Covid-19 vaccine.
A 63-year-old nursing home patient with cerebrovascular disease developed symptoms, including high fever, after being given the AstraZeneca vaccine, Yonhap news agency reported. The person was moved to a larger hospital on Tuesday, but died after showing symptoms of blood poisoning and pneumonia, Yonhap said.
Another person in their 50s with a cardiac disorder and diabetes died on Wednesday after suffering multiple heart attacks, having received the same vaccine a day earlier, the agency said.
An official with the Korea Disease Control and Prevention Agency (KDCA) told Reuters it was investigating the cause of the deaths, but did not elaborate or confirm the details of Yonhap's report.
An AstraZeneca spokeswoman in Seoul said the company had no comment at present.
South Korea began vaccinating its population last week. By Tuesday midnight, 85,904 people had received first doses of the AstraZeneca vaccine and 1,524 had been given Pfizer shots, KDCA said in a statement.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
South Korea reported 444 new confirmed Covid-19 cases on Tuesday, up from 344 on Monday, raising the country's tally to 90,816 infections, with 1,612 deaths.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Middle East-linked energy supply shocks put Asean Power Grid back in focus
Beijing’s calculated silence on the Iran war
DPM Gan warns of 3 structural shifts to the global system that will bring greater challenges – and opportunities